Endocyte (ECYT)
Add to Watchlists Create an Alert
14.04
+0.02 +0.14%
NASDAQ
May 24, 12:58PM
BATS Real time
Currency in USD
Endocyte Revenue Quarterly YoY Growth:
7467% for Dec. 31, 2012Endocyte Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 7467% |
| Sept. 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| Dec. 31, 2011 |
| Sept. 30, 2011 | |
| June 30, 2011 | |
| March 31, 2011 | |
| Dec. 31, 2010 | |
| Sept. 30, 2010 | -100.0% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
ECYT Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Lannett Company | 31.84% |
| Merck | -9.04% |
| Catalyst Pharmaceutical Partners |
ECYT Revenue Quarterly YoY Growth Rankings
| Overall |
99th percentile 8 of 8009 |
| Sector |
99th percentile 2 of 687 in Healthcare |
| Industry |
98th percentile 1 of 69 in Drug Manufacturers - Specialty & Generic |
ECYT Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -100.0% | Sep 2010 |
| Maximum | 7467% | Dec 2012 |
| Average | 3683% |